# Bone Phenotype in Autosomal Dominant Polycystic Kidney Disease

**Authors:** Magdalena Jankowska, Per Magnusson, Malgorzata Debowska, Bengt Lindholm, Abdul Rashid Qureshi, Tomasz Lukaszuk, Alicja Dębska-Ślizień, Daniel Guido Fuster, Peter Stenvinkel, Mathias Haarhaus

PMC · DOI: 10.1007/s00223-025-01471-w · Calcified Tissue International · 2026-01-23

## TL;DR

This study explores bone health in people with a kidney disease called ADPKD, finding that bone changes are more linked to kidney function than the severity of kidney cysts.

## Contribution

The study is the first to comprehensively characterize the bone phenotype in ADPKD across different disease stages.

## Key findings

- ADPKD patients showed lower bone turnover biomarkers like PINP and BALP.
- Bone mass and microarchitecture remained similar to healthy individuals despite disease progression.
- Bone alterations were more closely associated with kidney function decline than cystic burden.

## Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is a systemic ciliary disorder, yet the impact on bone health remains insufficiently defined. Given the expression of polycystins in osteocytes, osteoclasts and extracellular matrix, a disease-specific bone phenotype has been hypothesized. This study aimed to comprehensively characterize the bone phenotype in ADPKD across stages of chronic kidney disease (CKD) and Mayo Imaging Classification (MIC). In this cross-sectional study, 81 patients with ADPKD, 15 with CKD of other etiologies, and 21 healthy individuals were included. Bone phenotype was assessed across four domains: bone metabolism biomarkers, bone turnover biomarkers, bone mass/microarchitecture (dual-energy X-ray absorptiometry with trabecular scoring (TBS)) and bone material strength (microindentation, BMSi). Z-score-based heat-maps were used to visualize stage-specific alterations, and multivariable regression analysis was applied to estimate model parameters. ADPKD patients consistently showed lower bone turnover, particularly PINP and in CKD G1-2 also BALP, while BMSi, BMD and TBS did not differ from healthy individuals. Across CKD stages, mineral abnormalities reflected the effect of declining eGFR, whereas stratification by MIC revealed less distinct patterns, indicating that the bone phenotype may be more closely linked to CKD progression than cystic burden in later CKD stages. This first comprehensive analysis of the ADPKD bone phenotype reveals mineral disturbances, reduced bone turnover, and preserved bone mass and microarchitecture in early ADPKD. Bone alterations followed kidney function rather than MIC stage. Impact microindentation, BMSi, did not reveal any distinctive pattern in ADPKD.

The online version contains supplementary material available at 10.1007/s00223-025-01471-w.

## Linked entities

- **Diseases:** Autosomal dominant polycystic kidney disease (MONDO:0004691), chronic kidney disease (MONDO:0005300)

## Full-text entities

- **Genes:** CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, ALPP (alkaline phosphatase, placental) [NCBI Gene 250] {aka ALP, PALP, PLAP, PLAP-1}, PTH (parathyroid hormone) [NCBI Gene 5741] {aka FIH1, PTH1}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, ACP5 (acid phosphatase 5, tartrate resistant) [NCBI Gene 54] {aka HPAP, TRACP5a, TRACP5b, TRAP, TRAcP, TrATPase}, KL (klotho) [NCBI Gene 9365] {aka HFTC3, KLA}, FGF23 (fibroblast growth factor 23) [NCBI Gene 8074] {aka ADHR, FGFN, HFTC2, HPDR2, HYPF, PHPTC}, SOST (sclerostin) [NCBI Gene 50964] {aka CDD, DAND6, SOST1, VBCH}
- **Diseases:** IgA nephropathy (MESH:D005922), bone fragility (MESH:C536063), low bone turnover (MESH:D001851), MIC (MESH:C564543), systemic disorder (MESH:D009422), secondary hyperparathyroidism (MESH:D006962), cyst (MESH:D003560), Reduced bone turnover (MESH:D001523), kidney function decline (MESH:D007680), ADPKD (MESH:D016891), obesity (MESH:D009765), DE (MESH:D003635), polycystin deficiency (MESH:D007153), Kidney Disease (MESH:D007674), fracture (MESH:D050723), allergy (MESH:D004342), albuminuria (MESH:D000419), CKD (MESH:D051436), skeletal abnormalities (MESH:D009139), ciliary disorder (MESH:D002925), DM (MESH:D003920), bone turnover (MESH:D001847), hypophosphatemia (MESH:D017674), CKD-MBD (MESH:D012080), mineral disturbances (MESH:C537337), leg oedema (MESH:C536897)
- **Chemicals:** 25-hydroxyvitamin D3 (MESH:D002112), creatinine (MESH:D003404), 25(OH)D (-), Mg (MESH:D008274), Pi (MESH:D010716), Ca (MESH:D002118), tolvaptan (MESH:D000077602), PMMA (MESH:D019904), vitamin D (MESH:D014807), BMS (MESH:C095300), phosphate (MESH:D010710)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12827306/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12827306/full.md

## References

1 references — full list in the complete paper: https://tomesphere.com/paper/PMC12827306/full.md

---
Source: https://tomesphere.com/paper/PMC12827306